[Skip to Navigation]
Sign In
Comment & Response
October 29, 2020

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers

Author Affiliations
  • 1The State Key Laboratory of Translational Medicine and Innovative Drug Development, Ministry of Science and Technology, Jiangsu Simcere Diagnostics Co, Ltd, Nanjing, China
JAMA Oncol. 2020;6(12):1982. doi:10.1001/jamaoncol.2020.4818

To the Editor We read with interest the Original Investigation from Yu et al1 wherein they reported results of a phase 1/2 trial to assess the effects of the combination of osimertinib and bevacizumab as first-line treatment for patients with metastatic EGFR-mutant lung cancers. However, the 19-month median progression-free survival (PFS) in the study was comparable with the median PFS with osimertinib alone (19 months) in the FLAURA study.2 We wish to put forth the following discussion points.

Add or change institution